The authors also found that patients with at least one respiratory comorbidity, such as bronchial asthma, COPD, or interstitial lung disease, tended to present high Myl9 levels after 6 months of COVID-19 pneumonia, although this difference was not significant according to multivariate regression analysis (Table 5). This evidence concerns the gene MYL9 and chronic obstructive pulmonary disease.